Phoenix Life Sciences International Limited (PLSI)
Phoenix Life Sciences International Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Las Vegas, NV, US. The stock last traded at $0.00, down 99.99% on the session, giving a market capitalisation of $365,910. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of 204.07 implies it has historically moved more than the broad market.
Phoenix Life Sciences International Limited operates as a global healthcare solutions provider, conducting business in the United States and internationally. The company primarily concentrates on pioneering research, developing integrated programs, and producing goods aimed at the prevention and treatment of a broad spectrum of conditions. These include diabetes, pain, and various cancers, as well as psychological, gastrointestinal, autoimmune, neurological, and sleep disorders. Its diverse product line encompasses oral soft gel capsules, thin film dissolvable strips, transdermal patches, sublingual oral sprays, suppositories, and topical creams. Established in 2009, the company was initially known as Stem Bioscience, Inc., before officially adopting the name Phoenix Life Sciences International Limited in May 2018. Its corporate headquarters are located in Las Vegas, Nevada.
Phoenix Life Sciences International Limited is most often compared with the following Healthcare names: